Stryker Neurovascular
announced today that its Trevo^® Pro Retriever has been granted 510(k) market
clearance by the U.S. Food and Drug Administration. The Trevo^® Pro Retriever
is the next generation in clot removal technology from Stryker, utilizing
proprietary Stentriever^® Technology for optimized clot integration and
retrieval in patients experiencing acute ischemic stroke.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in